title: Management of Relapsed Diffuse Large B-cell Lymphoma.
abstract: Second-line therapy options for patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to, or relapses after, current rituximab-containing primary therapy continue to evolve. For younger patients, salvage therapy followed by intensive therapy and autologous stem cell transplant (ASCT) remains the treatment of choice for those with chemotherapy-sensitive disease. Combination therapy may be used for those who are not candidates for ASCT. In contrast, patients with DLBCL refractory to 2 lines of therapy have a very poor prognosis and generally short survival, and should be carefully considered for participation in clinical trials of novel approaches.
authors.affiliation: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Room 5-209, Toronto M5G 2M9, Canada. Electronic address: michael.crump@uhn.ca.
authors.forename: Michael
authors.initials: M
authors.lastname: Crump
mesh_terms: D064592:Autografts; D018572:Disease-Free Survival; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000628:therapy*; D000069283:Rituximab / Q000627:therapeutic use*; D016879:Salvage Therapy / Q000379:methods*; D033581:Stem Cell Transplantation; D015996:Survival Rate
chemical_list: D000069283:Rituximab
keywords: Autologous transplant; CD20 antibody; Prognosis; Relapsed/refractory DLBCL; Salvage chemotherapy